Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ASTRAZENECA ENTERS STRATEGIC IMMUNO-ONCOLOGY COLLABORATION WITH CELGENE CORPORATION TO DEVELOP PD-L1 INHIBITOR PROGRAMME FOR PATIENTS WITH SERIOUS BLOOD CANCERS AstraZeneca and MedImmune, the...
-
ASTRAZENECA AND Innate Pharma ANNOUNCE GLOBAL CO-DEVELOPMENT AND COMMERCIALISATION COLLABORATION FOR iph2201 IN IMMUNO -ONCOLOGY AstraZeneca and MedImmune, the Company's global biologics research...
-
AstraZeneca First Quarter Results 2015 Tomorrow, Friday, 24 April 2015, AstraZeneca will release first quarter results for 2015 at 07:00 bst. An analyst presentation of the first quarter results...
-
SELUMETINIB granted Orphan Drug Designation by US FDA for treatment of UVEAL MELANOMA AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the...
-
Tremelimumab granted Orphan Drug Designation by US FDA for treatment of malignant mesothelioma AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation...
-
FDA ADVISORY COMMITTEE REVIEWS SAVOR OUTCOMES STUDY RESULTS FOR ONGLYZA® (SAXAGLIPTIN) AND KOMBIGLYZE® XR (SAXAGLIPTIN AND METFORMIN HCI EXTENDED -RELEASE) AstraZeneca today announced that the US...
-
Transaction by Persons Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 27 March 2015, the individuals listed below, who are all persons discharging managerial responsibilities,...
-
NOTICE OF ANNUAL GENERAL MEETING AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2015 and Shareholders' Circular; a covering letter from the...
-
ASTRAZENECA AND DAIICHI SANKYO TO JOINTLY COMMERCIALISE MOVANTIK IN THE US AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for MOVANTIK™ (naloxegol) in the US,...
-
ASTRAZENECA ANNOUNCES POSITIVE PHASE III TOP-LINE RESULTS FOR PT003 FROM THE PINNACLE 1 AND PINNACLE 2 STUDIES IN COPD AstraZeneca today announced positive top-line results from the Phase...